Bayer says 'no sale' on diabetes unit; Teva jacks up Copaxone, Azilect prices;

@FiercePharma: Will Bausch + Lomb choose IPO over a sale to pharma? Related Q: Can Warburg Pincus get its $10B+ asking price? More | Follow @FiercePharma

@EricPFierce: COO Perez says Cubist well positioned in new hospital-centric payer world. "The world has turned and we are Cinderella now." | Follow @EricPFierce

 @AlisonBFierce: Altravax landed $1.2M from NIAID to advance its dengue vaccine and hepatitis therapeutic. More | Follow @AlisonBFierce

> After evaluating options for its diabetes unit, Bayer no longer plans to sell the business, Bayer Healthcare CEO Joerg Reinhardt said. Report

> Teva Pharmaceutical Industries ($TEVA) hiked the prices of its two lead drugs, the MS treatment Copaxone and Parkinson's disease drug Azilect, by 10% to help make up for anticipated losses to competition from oral treatments. Report

> A U.S. appeals court put the pharma industry on the hook for rebates and price caps issued by the Department of Defense to curb spending on drugs. Report

> India's Biocon won approval in its home country for Itolizumab, a biologic treatment for psoriasis; a launch there will pave the way for submission to FDA, the company said. Report

> China's drug agency is calling on the World Health Organization to buy more drugs made in China. Report

> GlaxoSmithKline ($GSK) won regulatory approval in India to purchase an additional 31.8% stake in its Indian subsidiary to boost its ownership to 75%. Report

Medical Device News

 @FierceMedDev: Samsung med device sales spike in 2012. Item | Follow @FierceMedDev

@MarkHFierce: Abbott is beginning a bioresorbable stent trial in the U.S. Big news for the company and its stent rivals alike. More | Follow @MarkHFierce

 @DamianFierce: $LIFE is teaming up with Boston Children's Hospital to develop genomics-based diagnostics. News | Follow @DamianFierce

> LabCorp inks companion diagnostic deal with Verastem. News

> JPM: U.S., EU regulators to consider GE's Alzheimer's imaging agent. Story

Biotech News

 @FierceBiotech: Buyout buzz: Biopharma players staying focused on bolt-on deals. Report | Follow @FierceBiotech

@JohnCFierce: Medicines Co. spikes after anti-clotting drug impresses in second run at PhIII. Story | Follow @JohnCFierce

> Baxter preps BLA on successful end to PhIII hemophilia drug study. More

> Payer risk outrivals regulatory jitters as biggest biotech hurdle. News

Drug Delivery News

> Alnylam prepares for U.K. Phase I and plans for the future. Article

> Agile snags $15M loan to push pipeline products forward. News

> FDA approves EMD Serono-Pfizer's Rebif auto-injector. Item

> FDA grants orphan label to eye cancer chemo-delivery combo. Story

Biomarkers News

> Biomarkers could tag chemo heart risk. Item

> Stem cell factor could improve ovarian cancer prognosis. Article

> Crescendo Bioscience deploys $28M Series D to market RA Dx biomarker test. News

> New target could improve treatment of deadly pancreatic cancer. Story

And Finally... DNA pioneer James Watson figures antioxidant vitamins and therapies could hinder cancer treatment. Report

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.